ChAd155 RSV

Drug Profile

ChAd155 RSV

Alternative Names: ChAd155-RSV; GSK3389245A

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Protein-vaccines; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Respiratory syncytial virus infections

Most Recent Events

  • 27 Sep 2016 Phase-I/II clinical trials in Respiratory syncytial virus infections (In infants, Prevention) in USA (IM) after September 2016 (NCT02927873; EudraCT2016-000117-76)
  • 27 Sep 2016 Phase-I/II clinical trials in Respiratory syncytial virus infections (Prevention, In infants) in Spain (IM) (EudraCT2016-000117-76)
  • 01 Jul 2015 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention) in United Kingdom (IM) (NCT02491463)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top